Day: January 3, 2022

AVCtechnologies Announces Filing of Resale Registration Statement as Part of Funding Plan

Written by Customer Service on January 3, 2022. Posted in Public Companies.

ATLANTA, Jan. 03, 2022 (GLOBE NEWSWIRE) — American Virtual Cloud Technologies (AVCtechnologies; Nasdaq: AVCT) announced that it has filed a resale registration statement on Form S-3 as part of several initiatives to raise growth capital and improve liquidity through an increased share float. Pursuant to its recent S-3 filing, AVCtechnologies has completed the registration of 37,916,668 shares which underlie warrants that were previously issued in accordance with previously announced financing transactions. These financings are a critical step in the company’s fundraising plan and will enable it to execute on its strategic growth initiatives such as the recently announced partnerships with Braidio and Etisalat. If all the warrants issued in the previously announced financing transactions are exercised, AVCtechnologies would receive...

LexaGene Starts the Year with Additional MiQLab Sales

Written by Customer Service on January 3, 2022. Posted in Public Companies.

BEVERLY, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce three additional purchase orders for MiQLab™ Systems from veterinary clinics in Michigan, Minnesota, and New York. Julie Griggs, LexaGene’s Global Director of Sales, stated, “My team is diligently engaged with numerous veterinary practices, both private and corporate. Many of the veterinarians we have spoken to share our excitement over the value of in-clinic PCR testing and the capabilities that the MiQLab System can provide to their practices. It is gratifying to welcome 2022 with a strong start and continue our momentum as we work on closing additional sales.” Dr. Jack Regan, LexaGene’s...

IES Holdings Appoints Jennifer A. Baldock to its Board of Directors

Written by Customer Service on January 3, 2022. Posted in Public Companies.

HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced the appointment of Jennifer A. Baldock to its Board of Directors, effective December 31, 2021. “We’re excited to welcome Jenny to our Board,” said Jeff Gendell, IES’s Chairman and CEO. “I’m confident that her board leadership experience, corporate governance knowledge and legal background will enhance the skills and expertise of our Board.” Ms. Baldock has been a member of the Board of Managers of CCF Holdings, LLC and its predecessors since 2013, where she is the chair of the Nominating and Governance Committee and a member of the Compliance Committee and the Compensation Committee. In addition, Ms. Baldock has been a member of the Board of Greenwich Emergency Medical Service since 2002 and has served as its...

IHC Announces Completion of the Sale of Madison National Life Insurance Company, Inc.

Written by Customer Service on January 3, 2022. Posted in Public Companies.

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) — Independence Holding Company (NYSE: IHC) today announced the completion of the sale of its subsidiary Madison National Life Insurance Company, Inc. (“Madison National Life”) to Horace Mann Educators Corporation (“Horace Mann”). All conditions to the consummation of the sale were satisfied and the transaction closed effective January 1, 2022. Roy T. K. Thung, Chief Executive Officer, commented, “We are very pleased that the transaction closed on schedule and appreciate all the efforts made by both companies to successfully complete the sale. We believe that the sale of Madison National Life to Horace Mann is beneficial to both companies. We are confident that Madison National Life will have continued growth under Horace Mann’s ownership.” About Independence Holding Company Independence...

Renowned Podcast Dawn of Drones To Feature Draganfly

Written by Customer Service on January 3, 2022. Posted in Public Companies.

Los Angeles, CA., Jan. 03, 2022 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce that Draganfly Chairman and CEO, Cameron Chell, will participate in the Dawn of Drones podcast presented by DroneLife and hosted by retired U.S. Air Force Colonel Dawn Zoldi on January 5, 2022, at 8 am PST / 11 am EST. The Dawn of Drones podcast connects a global audience directly with the game-changing people and platforms making a difference in the advanced air mobility, drone, and autonomous industries. It provides the latest developments on impacting the industry and supplies critical information for businesses to succeed in it. Cameron Chell, Chairman and CEO of Draganfly, and Dawn Zoldi will discuss...

Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 3, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:45 a.m. ET. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News and Presentations section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. Relay Therapeutics...

Otonomy to Participate in the H.C. Wainwright BioConnect Conference

Written by Customer Service on January 3, 2022. Posted in Public Companies.

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright BioConnect Virtual Conference. A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022. A link to the presentation will also become available at the same time through the Events page of the company’s website (www.otonomy.com). About Otonomy Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure...

Watsco Declares $1.95 Quarterly Dividend 48th Consecutive Year of Paying Dividends

Written by Customer Service on January 3, 2022. Posted in Dividend Reports And Estimates.

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) — Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $1.95 on each outstanding share of its Common and Class B common stock payable on January 31, 2022 to shareholders of record at the close of business on January 14, 2022. Watsco has paid dividends for 48 consecutive years. The Company’s philosophy is to share increasing amounts of cash flow with shareholders through higher dividends while maintaining a conservative financial position. Future dividends will be considered in light of investment opportunities, cash flow, general economic conditions and the Company’s financial condition. About Watsco Watsco is the largest distribution network for heating, air conditioning and refrigeration (HVAC/R) products with locations in the United States, Canada, Mexico and Puerto...

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 3, 2022. Posted in Public Companies.

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET. The presentation and question and answer session will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event. A copy of the presentation slides will be also posted on the company’s website beginning on Monday, January 10, 2022, at 8:00 a.m. ET. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science,...

Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 3, 2022. Posted in Public Companies.

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Bruce Goldsmith, Ph.D., president, and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 10:30 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless...

Day: January 3, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice